Психиатрия Психические расстройства в общей медицине
№02 2019

Список исп. литературыСкрыть список

1.Jean C. Yi, PhD and Karen L. Syrjala Anxiety and Depression in Cancer Survivors Med Clin North Am. 2017; 101 (6): 1099–1113. doi: 10.1016/j.mcna.2017.06.005
2.Пономарева Л.А., Сухарева Е.А., Егорова А.Г., Сомов А.Н. Опыт реализации мер по снижению смертности от рака молочной железы. Онкология. Журнал им. П.А. Герцена. 2015; 4(6): 42–47. doi:10.17116/onkolog20154642-47 [Ponomareva L.A., Sukhareva E.A., Egorova A.G., Somov A.N.] Experience in implementing measures to reduce mortality from breast cancer. Oncology. Journal P.A. Herzen. 2015; 4 (6): 42–47. doi:10.17116/onkolog20154642-47
3.Chad Friedman E, Coleman S, Trarger LN et al. Psychological distress associated with cancer screening: A systematic review. Canser. 2017; 123 (20): 3882–3894. doi: 10.1002/cncr.30904. Epub 2017 Aug 22.
4.Шушпанова О. В. Психические нарушения у больных раком молочной железы: дифференцированный подход к изучению нозогений Журнал неврологии и психиатрии им. С.С. Корсакова. 2017; 117 (8): 18–26. doi: 10.17116/jnevro20171178118-26 [Shushpanova O.V.] Mental disorders in patients with breast cancer: a differentiated approach to the study of nosogeny. Journal of Neurology and Psychiatry. S.S. Korsakova. 2017; 117 (8): 18–26. doi: 10.17116/jnevro 20171178118-26
5.Нелюбина Л.А., Лактионов К.П. Причины заболевания раком молочной железы и возможности его профилактики. Вестник РОНЦ им.Н.Н.Блохина РАМН. 2013; 24 (92): 3–10. [Nelyubina L.A., Laktionov K.P.] Causes of breast cancer and the possibility of its prevention. Bulletin of the Russian Research Center N.N. Blokhina RAMS. 2013; 24 (92): 3–10.
6.Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2017; 236 с. The status of cancer care for the population of Russia in 2016. Ed. HELL. Kaprina, V.V. Starinsky, G.V. Petrova. M.: Moscow P.A. Herzen – a branch of the FSBI "NIIRTS" of the Ministry of Health of Russia, 2017; 236 p.
7.Галиуллина С.Д. Нервно-психические нарушения у больных раком молочной железы: Автореферат дис. канд. мед. наук, Уфа, 2000; 23 с. [Galiullina, S.D.] Neuropsychiatric disorders in patients with breast cancer: Abstract dis. Cand. Med.. Sciences, Ufa, 2000; 23 p.
8.Терентьев И. Г., Алясова А.В., Трошин В.Д. Нервно-психические расстройства у больных раком молочной железы .Нижний Новгород.: Изд-во Нижегородской государственной медицинской академии, 2004; 264 с. [Terentyev I.G., Alyasova A.V., Troshin V.D. ] Neuropsychiatric disorders in patients with breast cancer. Nizhny Novgorod .: Publishing house of the Nizhny Novgorod State Medical Academy, 2004; 264 p.
9.Bringmann H, Singer S, HЪckel M. [et al ]. Longitudinal analysis of psychiatric morbidity in cancer patients. Onkologie. 2008; 31 (6): 343–4. doi: 10.1159/000132166.
10.Самушия М. А., Зубова И. В. Нозогении (психогенные реакции) при раке молочной железы. Психические расстройства в общей медицине. 2009; 1: 24–29. [Samushia M. A., Zubova I. V.] Nosogeny (psychogenic reactions) in breast cancer. Mental disorders in general medicine. 2009; 1: 24–29.
11.Володин Б.Ю. психосоматические взаимоотношения у онкологических больных. Паллиативная медицина и реабилитация. 2007; 3: 51–54. [Volodin B.Yu.] psychosomatic relationships in cancer patients. Palliative medicine and rehabilitation. 2007; 3: 51–54.
12.Тарабрина Н.В., Ворона О.А., Курчакова М.С. [и др.]. Онкопсихология: посттравматический стресс у больных раком молочной железы ISBN: 978-5-9270-0184-2 175 с (моногр) под ред Клочкова И.С., Институт психологии РАН, 2010. [Tarabrina N.V., Vorona O.A., Kurchakova M.S. [et al] Oncopsychology: post-traumatic stress in patients with breast cancer ISBN: 978-5-9270-0184-2 175 s (monograph) edited by I. Klochkova, Institute of Psychology RAS, 2010
13.Kang J, Sung N, Park S et al. The epidemiology of psychiatric disorders among women with breast cancer in South Korea: analysis of national registry data. Psychooncology. 2014; 23 (1): 35–9. doi: 10.1002/pon.3369.
14.Butow P, Kelly S, Thewes B et al. Attentional bias and metacognitions in cancer survivors with high fear of cancer recurrence. Psychooncology. 2015; 24 (4): 416–23. doi: 10.1002/pon.3659.
15.Sanjida S, Janda M, Kissane D et al. A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology. 2016; 25 (9): 1002–1016. doi: 10.1002/pon.4048.
16.Ramaswami R, Villarreal MD, Pitta DM et al. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015; 152 (2): 231–7. doi: 10.1007/s10549-015-3465-5
17.L’Espérance S, Frenette S, Dionne A, Dionne JY. Comité de l’évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013; 21:1461–1474. doi: 10.1007/s00520-013-1732-8.
18.Wiśniewska I, Jochymek B, Lenart-Lipińska M et al. Chabowskicorresponding M. The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. Breast Cancer. 2016; 23: 178–182. doi: 10.1007/s12282-015-0655-2
19.Kimmick GG, Lovato J, McQuellon R et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006; 12 (2): 114–22. doi: 10.1111/j.1075-122X. 2006.00218.x
20.Biglia N, Bounous VE, Susini T et al. Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. Eur J Cancer Care (Engl). 2018; 27 (1). doi: 10.1111/ecc.12484.
21.Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996; 64 (2): 293–302. doi: 10.1016/0304-3959(95)00138-7
22.Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res. Treat. 2001; 70 (1): 1–10. doi: 10.1023/a:1012518831494
23.Roscoe J., Morrow GR, Hickok JT et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005 Feb; 89 (3): 243–9. doi: 10.1007/s10549-004-2175-1
24.Möslinger-Gehmayr R, Zaninelli R, Contu A et al. A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression Zentralbl Gynakol. 2000; 122 (4): 195–202.
25.Grassi L, Nanni MG, Rodin G et al. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 2018; 29 (1): 101–111. doi: 10.1093/annonc/mdx526.
26.Medical Services Commission. Palliative care for the patient with incurable cancer or advanced disease. Part 2: Depression. Victoria (BC): British Columbia Medical Services Commission. 2011 [cited 2013 Nov 3]. Available from: http://www.bcguidelines.ca/pdf/palliative2_ depression.pdf
27.Fulcher CD, Badger T, Gunter AK et al. Putting evidence into practice: interventions for depression. Clin J Oncol Nurs 2008; 12 (1): 131–40. doi: 10.1188/08.CJON.131-140.
28.Caraci F, Crupi R, Drago F et al. Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract. Current Drug Metabolism. 2011; 12 (6): 570–577. doi: 10.2174/138920011795713706
29.Irarrázaval OME. .Antagonism of tamoxifen and antidepressants among women with breast cancer. Rev Med Chil. 2011; 139(1): 89-99. doi: /S0034-98872011000100013.
30.Wedret JJ, Tu TG, Paul D et al. Interactions between antidepressants, sleep aids and selected breast cancer therapy. Ment Illn. 2019; 11(1): 8115. doi: 10.4081/mi.2019.8115.
31.Torta R, Siri I, Caldera P. Sertraline effectiveness and safety in depressed oncological patients. Support Care Cancer. 2008; 16 (1): 83–91. doi: 10.1007/s00520-007-0269-0.
32.Schillani G, Capozzo MA, Era D et al. Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: report of 18 cases. Tumori. 2011; 97 (3): 358–361. doi: 10.1700/912.10034.
33.Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005; 62:190-198. DOI: 10.1001/archpsyc.62.2.190
34.Grassi L, Caruso R, Hammelef K et al. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry. 2014; 26(1): 44–62. doi: 10.3109/09540261.2013.842542
35.Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008; 112 (1): 197–201. doi: 10.1007/s10549-007-9841-z.
36.Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs. 2007; 21: 581-609. doi: 10.2165/00023210-200721070-00004
37.Torta R, Leombruni P, Borio R, Castelli L. Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial. Hum Psychopharmacol. 2011; 26: 291–299. doi: 10.1002/hup.1202
38.Spiegel D, Riba MB. Managing anxiety and depression during treatment. Breast J. 2015; 21(1): 97–103. doi: 10.1111/tbj.12355
39.Rustad JK, David D, Currier MB. Cancer and post-traumatic stress disorder: diagnosis, pathogenesis and treatment considerations. Pall Supp Care. 2012; 10 (3): 213–223. doi: 10.1017/S1478951511000897
40.Baldwin D.S., Anderson I.M., Nutt D.J. [et al]. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014; 28(5): 403–439. doi: 10.1177/0269881114525674
41.Ersoy MA, Noyan AM, Elbi H. An Open-Label Long-Term Naturalistic Study of Mirtazapine Treatment for Depression in Cancer Patients. Clin Drug Investig. 2008; 28 (2): 113–20. doi: 10.2165/00044011-200828020-00005.
42.Carvalho AF, Hyphantis T, Sales PM et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. Cancer Treat Rev. 2014; 40 (3): 349–55. doi: 10.1016/j.ctrv.2013.09.009/